Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis
Titel:
Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis
Auteur:
Papadimitrakopoulou, V.A. Mok, T.S. Han, J.-Y. Ahn, M.-J. Delmonte, A. Ramalingam, S.S. Kim, S.W. Shepherd, F.A. Laskin, J. He, Y. Akamatsu, H. Theelen, W.S.M.E. Su, W.-C. John, T. Sebastian, M. Mann, H. Miranda, M. Laus, G. Rukazenkov, Y. Wu, Y.-L.